Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Bruce C TiuLeyre ZubiriJames IhekeVartan PahalyantsNicholas TheodosakisPearl Ugwu-DikeJayhyun SeoKimberly TangMeghan E SiseRyan J SullivanJarushka NaidooMeghan J MooradianYevgeniy R SemenovKerry Lynn ReynoldsPublished in: Journal for immunotherapy of cancer (2022)
In a large claims-based analysis, PD-1/PD-L1 inhibitors increase the risk of pneumonitis in patients with lung cancer by 2.49%. Cases of CIP are associated with high healthcare utilization, discontinuation of ICIs, and mortality.